NEW YORK, June 10 /PRNewswire-FirstCall/ -- AngioGenex Inc. (OTC Bulletin Board: AGGX.OB) a New York-based biotechnology company, and the leader in the field of Id targeted anti-angiogenic drugs, announced the appointment of William Garland PhD as Chief Executive Officer. Dr. Garland, formerly with Hoffmann La Roche, Inc., has directed research and development programs for a number of early stage biotech companies such as Centaur Pharmaceuticals, Atairgin Technologies, Lpath Therapeutics, Inc. (LPTN.OB) and Tosk in addition to AngioGenex. He was also instrumental in raising capital for those companies. His career highlights include the successful development of many drugs from discovery through all phases of preclinical and clinical testing, to regulatory approval. Dr. Garland began working with the AngioGenex as a consultant, and later became V.P. Head of Research and Development, Chief Operating Officer, and a member of the company's Board of Directors. He said that: "Since joining the company I have seen the technology progress from identifying the Id proteins as outstanding anti- angiogenic targets, to discovering and patenting proprietary anti-Id agents, including preclinical leads that we are presently testing in vivo."
The Company's product candidates AGX8 and AGX51 are proprietary small
molecule inhibitors of the pro-angiogenic Id proteins. Extensive research
and numerous major scientific publications by researchers at Memorial Sloan
Kettering Cancer Center, led by Dr. Robert Benezra, have proven that the
targeted Id proteins are required for the creation of new blood vessels
that allow tumors to grow and to metastasize, or spread. The Company
discovered these drugs through rational and computational screening
approaches and they have shown extremely promising results in both in vitro
and in vivo preclinical studies. These data prove that these drug
candidates are potent inhibitors of angiogenesis. "Establishing the
effectiveness of these molec
|SOURCE AngioGenex, Inc.|
Copyright©2008 PR Newswire.
All rights reserved